ORIC Pharmaceuticals Stock
Biopharmaceutical company
About ORIC Pharmaceuticals Stock
ORIC Pharmaceuticals is a privately-held company dedicated to discovering and developing novel therapies for treatment-resistant cancers. While recent advances with targeted therapeutics have extended prognoses in many disease settings, cancers often develop resistance to current drugs. Relapsed patients lack further treatment options. ORIC has assembled a world-class scientific team dedicated to the discovery of therapies that can meaningfully improve clinical outcomes for these patients.
Investors
Casdin Capital
City Hill Ventures
Fidelity Management and Research Company
Hartford HealthCare Endowment
Invus
Moderna Therapeutics, Thrive Market, ORIC Pharmaceuticals, Cava Grill, PatientsLikeMe, Booster Fuels
Irving Investors
Memorial Sloan - Kettering Cancer Center
OrbiMed
Taiho Ventures
Topspin Partners
Funding History
| November 2014 | $15.4M |
|---|---|
| November 2015 | $54.0M |
| February 2018 | $53.4M |
| August 2019 | $55.0M |
Management
Chief Executive Officer
Jacob Chacko
Chief Scientific Officer
Lori Friedman
Chief Medical Officer
Pratik Multani
Chief Business Officer
Matthew Panuwat
Chief Financial Officer
Dominic Piscitelli
Press
businesswire - May, 13 2019
xconomy - May, 21 2018
Other Companies
EquityZen does not have an affiliation with, formal relationship with, or endorsement from ORIC Pharmaceuticals or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
